AI assistant
Oxurion NV — Director's Dealing 2024
Dec 4, 2024
3987_mrq_2024-12-04_8fda7e64-5d18-4c50-9fc7-bdbb2c75c29a.pdf
Director's Dealing
Open in viewerOpens in your device viewer

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
Leuven, BELGIUM – December 4, 2024 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:
Oxurion received a transparency notification on December 3, 2024, from Atlas Special Opportunities, LLC indicating that as of December 3, 2024, it held 97,098 shares of the then outstanding 2,002,550 shares, and therefore crossed under the threshold (5%) by virtue of the sale of voting securities.
About Oxurion
Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com.
Important information about forward-looking statements
Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forwardlooking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.
For further information please contact:
Oxurion NV Pascal Ghoson Chief Executive Officer [email protected]
________
- Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.
ANNEX 1
| FSMA | FINANCIAL SERVICES AND MARKETS AUTHORITY |
Transparency notification Form TR-1 BE PART I |
|
|---|---|---|---|
| 1) Status of the notification | |||
| Final | |||
| 2) Issuer | |||
| Name OXURION | |||
| ldentification number 0881-620-924 | |||
| 3) Reason for the notification | |||
| Acquisition or disposal of voting securities or voting rights | |||
| 4) Notification by | |||
| A person that notifies alone | |||
| 5) Persons subject to the notification requirement | |||
| Name | Address (for legal entities) | ||
| Atlas Special Opportunities LLC | 2500 Westchester Avenue, Suite 401, Purchase, NY 10577 | ||
| 6) Persons that dispose of votinq rights (only to be filled in if art. 7 of the Law applies) | |||
| Name | Address (for legal entities) | ||
| a | Please continue entering the information in part II concerning the persons referred to in Sections 5 and 6 | Part II | |
| 7) Date on which the threshold is crossed | |||
| 03/12/2024 (DD/MM/YYYY) | |||
| 8) Threshold that is crossed (in %) | |||
| 5 | |||
| I fif the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10 | |||
| 9) Denominator | |||
| 2,002,550 | |||
| Please enter the denominator before filling in the data | |||
| 10) Notified details | |||
| A) Voting rights | Previous notification | After the transaction |
| A) Voting rights | Previous notification | After the transaction | ||||
|---|---|---|---|---|---|---|
| # of voting rights | # of voting rights | % of voting rights | ||||
| Holders of voting rights | Linked to securities | Not linked to the securities |
Linked to securities | Not linked to the securities |
||
| Atlas Special Opportunities LLC | 175,690 | 97.098 | 4.85% | |||
| TOTAL | 97.098 | 0 | 4.85% | 0.00% |
| B) Equivalent financial instruments | After the transaction | ||||||
|---|---|---|---|---|---|---|---|
| Holders of equivalent financial instruments |
Type of financial instrument | Expiration date | Exercise period or date |
# of voting rights that may be acquired if the instrument is exercised |
% of voting rights | Settlement | |
| + | |||||||
| TOTAL | 0 | 0.00% | |||||
| The totale will be undatod onco you have clicked on ¿CALCULATES |
| TOTAL (A & B) | # of voting rights % of voting rights | ||
|---|---|---|---|
| CALCULATE | 97,098 | 4.85% |
11) Full chain of controlled undertakings through which the holding is effectively held, if applicable
12) In case of proxy voting for only one GM
| (DDMWWTTTT) | |||
|---|---|---|---|
| Holder | will cease to hold / will hold again |
voting rights as of |
13) Additional information
On 26 November 2024 (with settlement date on 20 November LC cold 34,000 stares in Oruinn N', as a result of which its shareholing decreased of 14,690 stares (= 77 & Manier 2018 Sema 2017, Alexandra Comments Comments Comment of the brandmich Grander Gercedor of Prosocies Carad of Prosoder of Prospector of Prospector of Research of Re

Signature Patvick Vance
For security reasons, the unsigned form in xlsx format should be
transmitted to [email protected]. You can do this manually
OR if you have MS Outlook at your disposal via the " Send" button.
In addition, a signed copy in PDE format should also be
transmitted.